NCT07841093尚未招募3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of JMKX003142 Tablet in the Treatment of Renal Edema
Jemincare1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2027年2月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Change of body weight from baseline
研究概览
简要总结
To evaluate the efficacy, safety, and of JMKX003142 administered randomly, double-blind, placebo-controlled study in Chinese renal edema patients with inadequate response to conventional diuretic therapy.
详细描述
JMKX003142 is an arginine vasopressin（AVP）-V2R antagonist which shows a remarkable diuretic effect in healthy volunteers（phase 1 study） and renal edema patients（phase 2 study）.In this phase 3 study ，we will observe the safety 、efficacy about JMKX003142 tablet in renal edema who have an inadequate response to conventional diuretic therapy. This phase 3 study is designed as a randomly, double-blind,placebo-controlled study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who can fully understand the purpose and process of the study and voluntarily sign the informed consent form（ICF）;
- •Age ≥ 18 years old during screening;
- •Diagnosed as renal edema during screening;
- •Estimated glomerular filtration rate（eGFR） ≥ 15 mL/min/1.73m2 during screening.
- •At the start of the run-in period,patients must have been receiving either a loop diuretic at a dose equivalent to ≥40 mg of furosemide or a combination of any dose of a loop diuretic with a diuretic of another class (different mechanism of action) as the background therapy medication.
- •Body weight change of <1.0 kg during the run-in period.No changes in the conventional diuretic regimen during the run-in period.
排除标准
- •Patients who are receiving the renal replacement therapy during screening or patients who require renal replacement therapy in the short term evaluated by the researchers;
- •Patients who are suspected with hypovolemia;
- •Patients with the following diseases or symptoms: acute thrombosis, diarrhea, and difficulty urinating;
- •Patients who are unable to sense thirst or who have difficulty with fluid intake;
- •Patients who have received arginine vasopressin-V2R blockers within 14 days prior to the randomization;
- •The following laboratory indicators are abnormal: glutamic pyruvic transaminase ≥ 1.5 ×upper limit of normal, glutamic oxaloacetic transaminase ≥ 1.5 × upper limit of normal, serum sodium> upper limit of normal;
- •Patients who received diuretics or treatments with diuretic effects（except for the background therapy medication） from Day-3 to randomization;
- •During screening, systolic blood pressure <90 mmHg;
- •Patients who have a history of allergies to ≥ 3 substances, or are currently in an allergic state;
- •Female patients who are breast-feeding or who have a positive pregnancy test result prior to receiving investigational product (IMP);
- •Sexually active males or women of childbearing potential (WOCBP) who do not agree to practice birth control or remain abstinent during the trial and for 30 days after the final IMP administration.
研究组 & 干预措施
JMKX003142 tablet group
Experimental
take orally once daily，last for 7 days
干预措施: JMKX003142 Tablets (Drug)
placebo group
Placebo Comparator
take orally once daily，last for 7 days
干预措施: Placebo Tablets (Drug)
结局指标
主要结局
Change of body weight from baseline
时间窗: Day 8
次要结局
- Change of body weight from baseline(Day 2 to day 7)
- Daily urine volume(Day 2 to day 7)
- Daily fluid balance(Day 1 to Day 7)
- Resolution rate of lower limb edema(Day 2 to day 8)
- Incidence rate of adverse events(From the first dose through 7 days after the last dose)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderDepressive Disorder, MajorNCT07573176Janssen Research & Development, LLC600
尚未招募
3 期
JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast CancerBreast CancerNCT07784036Chengdu JOYO pharma Co., Ltd.171
招募中
3 期
A Study of DA-302168S in Participants With Overweight/ObesityOverweight and ObesityNCT07629544Chendu DIAO Pharmaceutical Group CO., LTD.840
尚未招募
3 期
1% Clascoterone Cream for the Treatment Acne VulgarisAcne VulgarisNCT07457294Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.692
招募中
3 期
Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisSeasonal Allergic Rhinitis (SAR)NCT07678931Chengdu Kangnuoxing Biopharma,Inc.136